The pertussis vaccine protects against whooping cough, a highly contagious bacterial infection that can be life-threatening for infants. It’s never given on its own. Instead, it’s combined with vaccines for diphtheria and tetanus in two formulations: DTaP for babies and young children, and Tdap for preteens, teens, and adults. The uppercase and lowercase letters reflect different concentrations of each component, with DTaP containing higher doses suited for building immunity from scratch.
What’s Actually in the Vaccine
Modern pertussis vaccines are “acellular,” meaning they don’t contain whole bacteria. Instead, they use a few specific proteins from the surface of the bacterium that causes whooping cough. The key ingredient is an inactivated form of pertussis toxin, the protein responsible for much of the damage the infection causes. Depending on the manufacturer, the vaccine may also include other bacterial surface proteins: one that helps the bacterium attach to airways, one called pertactin from its outer membrane, and hair-like structures called fimbriae that the bacterium uses to grip cells.
Different vaccine brands contain different combinations and amounts of these proteins. Some include just two components, while others include three or four. All of them include the inactivated toxin as the core ingredient, along with diphtheria and tetanus components.
How It Trains Your Immune System
After vaccination, your immune system recognizes the bacterial proteins as foreign and mounts a response. Antibody-producing cells increase in your blood, peaking about seven days after the shot. These cells churn out antibodies specifically shaped to neutralize the pertussis proteins. Antibody levels in your blood peak around day 14, then gradually start to decline after about a month, though they remain elevated well above pre-vaccination levels.
This immune memory means that if you encounter the actual bacterium later, your body can respond faster and more forcefully than it could without vaccination. The antibodies target the toxin and surface proteins, preventing the bacterium from establishing a serious infection in your airways.
The Vaccination Schedule
Children receive five doses of DTaP at the following ages:
- 2 months
- 4 months
- 6 months
- 15 to 18 months
- 4 to 6 years
The first three doses build the foundation of immunity, while the fourth and fifth doses boost it during the years when children are increasingly exposed to other kids in group settings. Preteens then get a single Tdap booster, typically around age 11 or 12, to reinforce protection as immunity from childhood doses fades.
Tdap During Pregnancy
The CDC recommends that pregnant women receive Tdap during weeks 27 through 36 of each pregnancy, preferably earlier in that window. The goal is straightforward: the mother’s body produces fresh antibodies that cross the placenta and give the baby some protection during its first weeks of life, before the infant is old enough to start the DTaP series at two months. This is recommended with every pregnancy, even if pregnancies are close together, because antibody levels drop over time.
Why Protection Fades Over Time
One of the most important things to understand about the pertussis vaccine is that its protection is not permanent. After the fifth childhood dose, pertussis rates among vaccinated children rise substantially over the following years. Data from Minnesota showed that pertussis cases jumped from about 16 per 100,000 children in the first year after that final dose to 138 per 100,000 by year six. Oregon tracked a similar pattern, with cases rising from 6 per 100,000 to 24 per 100,000 over the same period.
This waning immunity is the central limitation of acellular pertussis vaccines. It’s why booster doses exist, and why vaccinating pregnant women with each pregnancy matters so much for newborn protection. Older whole-cell pertussis vaccines (used before the 1990s) appeared to provide longer-lasting immunity, but they also caused more side effects, which led to the switch to the current acellular versions.
Common Side Effects
For children getting DTaP, the most common reactions are soreness or swelling at the injection site, mild fever, fussiness, fatigue, loss of appetite, and occasional vomiting. These typically last one to three days. Severe injection site reactions are rare and may be less frequent when the shot is given in the leg rather than the arm.
For teens and adults getting Tdap, the side effect profile is similar: pain, redness, or swelling at the injection site, mild fever, headache, fatigue, and sometimes nausea or stomach discomfort. Severe allergic reactions are possible but rare with either formulation.
The Cocooning Strategy
Because newborns can’t receive their first pertussis dose until two months of age, they depend entirely on the immunity passed from their mother and on the people around them not carrying the infection. This is the idea behind “cocooning,” a strategy introduced in 2004 that encourages everyone who will be in close contact with a newborn during its first six months to be up to date on their pertussis vaccination. That includes partners, siblings, grandparents, and regular caregivers.
In practice, cocooning has proven only partially effective because it’s difficult to ensure that every person around a baby actually gets vaccinated. This is a major reason why maternal Tdap vaccination during pregnancy has become the primary strategy for protecting newborns. It doesn’t rely on the behavior of a whole circle of contacts. It puts antibodies directly into the baby’s bloodstream before birth.